Background: This phase 1 study evaluated the maximum tolerated dose (MTD), safety, and efficacy of bosutinib (competitive Src/ Abl tyrosine kinase inhibitor) plus capecitabine.
Preclinical findings show that inhibition of the proto-oncogene, nonreceptor tyrosine kinase Src (Summy and Gallick, 2003; Parsons and Parsons, 2004) , synergises with 5-FU to restore chemosensitivity in pancreatic cancer cells (Ischenko et al, 2008) and to increase cytotoxicity in breast cancer models (Somlo et al, 2013) . In addition, a study in non-small-cell lung cancer cells showed synergistic cytotoxic effects with the combination of the Src inhibitor dasatinib and the TS-inhibitor pemetrexed and demonstrated that pemetrexed-induced TS upregulation is blocked via Src inhibition; notably, in that study, pretreatment TS levels were positively correlated with Src levels, and increased Src and TS levels were significantly correlated with poorer survival in the donor patients (Ceppi et al, 2012) . These findings suggest a potential role for the combination of a TS inhibitor and a Src inhibitor in countering 5-FU resistance.
Src has been recognised as a potential therapeutic target in a number of solid tumour settings, as Src dysregulation promotes tumour progression, metastasis, invasion, and angiogenesis (Talamonti et al, 1993; Verbeek et al, 1996; Summy and Gallick, 2003; Trevino et al, 2006; Park et al, 2007; Finn, 2008; Guarino, 2010; Gleixner et al, 2011) . Src inhibition has been shown to exert antitumour activity in cellular and xenograft models of breast cancer (Finn et al, 2007; Huang et al, 2007; Jallal et al, 2007) and to exert antitumour and anti-invasive activity in colon (Golas et al, 2005; Serrels et al, 2006) , head and neck (Johnson et al, 2005; Song et al, 2013) , prostate (Nam et al, 2005) , non-small-cell lung (Johnson et al, 2005) , glioblastoma (Du et al, 2009) , and sarcoma (Shor et al, 2007) cancers in preclinical studies.
Dasatinib and bosutinib are dual inhibitors of the Src and Abl tyrosine kinases (Mayer and Krop, 2010 ). An initial phase 1 study has evaluated the combination of dasatinib (100-140 mg daily) with capecitabine (800-1000 mg m À 2 twice daily) in advanced breast cancer (n ¼ 52), resulting in an ORR of 22% and manageable tolerability (Somlo et al, 2013) . Although the ORR was similar to that reported with capecitabine monotherapy in other studies (Blum et al, 1999 (Blum et al, , 2001 Reichardt et al, 2003; Fumoleau et al, 2004; Amari et al, 2010) , the phase 1 study was not powered sufficiently to assess the efficacy contributions of dasatinib to the combination (Somlo et al, 2013) , suggesting that further evaluation of Src inhibitors in combination with capecitabine is needed.
Bosutinib , which is approved in the United States (Bosulif Full Prescribing Information, 2013) and Europe (Bosulif Summary of Product Characteristics, 2013) for use in Philadelphia chromosome-positive chronic myeloid leukaemia, has been shown to inhibit Src and the growth of pancreatic tumour xenografts (Messersmith et al, 2009) , the migration and invasion of breast cancer cells (Vultur et al, 2008) , and the growth and invasion of prostate cancer cells and xenografts (Rabbani et al, 2010) in preclinical models. In addition, bosutinib at a dose of 400 mg per day has shown limited activity (ORR: 5.5%; median progressionfree survival (PFS): 9.9 weeks) and a manageable tolerability profile in a phase 2 study of patients (n ¼ 73) with unselected, heavily pretreated advanced breast cancer (67% hormone receptorpositive; Campone et al, 2012) . Together, these preclinical and preliminary clinical findings support the feasibility of evaluating the combination of bosutinib and capecitabine in patients with select locally advanced or metastatic solid tumours. In the present study, the maximum tolerated dose (MTD) and the safety, tolerability, and antitumour activity of this combination are assessed in patients with advanced solid tumours.
MATERIALS AND METHODS
Study design. This study was originally planned as a phase 1/2, multicentre, open-label study (ClinicalTrials.gov; Unique ID: NCT00959946); the phase 1 portion was completed and the results are reported here. The phase 1 study used an 'up-down' doseescalation design (Ivanova and Wang, 2004) to determine the MTD of bosutinib plus capecitabine combination therapy in patients with selected solid tumours. The results of a simulation study showed that, compared with a specific 3 þ 3 design, this 'up-down' dose-escalation design allows more patients to be evaluated closer to the MTD and fewer at toxic dose levels (see Supplementary Materials). Bosutinib was administered orally once daily continuously, and capecitabine was administered orally twice daily on days 1 to 14 of each 21-day treatment cycle. Up to nine dose combinations, including three dose levels of bosutinib (200, 300, and 400 mg) and three dose levels of capecitabine (625, 750, and 1000 mg m À 2 ), were selected as possible dose levels. The initial dose cohorts with two patients each were (i) bosutinib 200 mg per day plus capecitabine 750 mg m À 2 twice daily and (ii) bosutinib 300 mg per day plus capecitabine 625 mg m À 2 twice daily. Additional cohorts could be enrolled at higher or lower dose levels based on the number of dose-limiting toxicities (DLTs; described below) observed during the first 21 days in the current cohort of two patients, the cumulative toxicity rate at that dose combination, and the current doses of bosutinib and capecitabine. Cohort enrollment was based on the rules presented in Table 1 (see Supplementary Materials for additional information). The 'up-down' dose-escalation design allowed up to nine dose combinations across the two drugs studied (Table 2 ). This design would also allow the possibility of achieving two concurrent MTD levels, one that would maximise bosutinib and the other that would maximise capecitabine, in the event that increasing both concurrently proved untenable. Patients were enrolled at the next dose level when two evaluable patients at the same dose level had been evaluated for the first 21-day treatment cycle and had received at least 14 doses of bosutinib and at least 10 doses of capecitabine or experienced a DLT, whichever occurred first, until a total of 24 evaluable patients were assessed. If a patient withdrew from the study before completing the 21-day period without experiencing a DLT, another patient was enrolled to replace that patient at the current dose combination.
DLTs were defined as any of the following treatment-related events that occurred during the first 21-day cycle: grade 3/4 nonhaematologic adverse event (AE), including nausea, vomiting, or diarrhoea despite optimal medical therapy, and asthenia lasting more than 3 days; grade 4 haematologic AE; or delayed recovery from one of the above AEs, causing delay of treatment by at least 3 weeks. The MTD for bosutinib plus capecitabine was defined as the highest dose level at which less than 33% of patients experienced a DLT. Written informed consent was obtained from all patients before enrollment. The protocol was reviewed and approved by the Ethics Committees/Institutional Review Boards of the participating institutions, and the study was conducted according to the Declaration of Helsinki and European Good Clinical Practice requirements.
Eligibility criteria. Eligible patients were men and women aged X18 years with a confirmed pathologic diagnosis of locally advanced or metastatic breast cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, or glioblastoma that was not curable with approved regimens. Patients were also required to have at least one radiologically measurable lesion as defined by the Response Evaluation Criteria In Solid Tumors (RECIST), version 1.0, and an Eastern Cooperative Oncology Group Performance Status score of 0 to 2. Bone or skin could not be the only site of disease, and patients with clinically unstable primary or metastatic central nervous system tumours were ineligible. No prior treatment with Src inhibitors was permitted; however, prior treatment with capecitabine or 5-FU was allowed unless stopped for toxicity. No chemotherapy, investigational therapy, major surgery, or radiation therapy within 14 days of study treatment initiation was allowed. Patients with any other major illness, including a history of clinically significant or uncontrolled cardiac disease, serious active infection, uncontrolled major seizure disorder, or significant pulmonary disorder, were ineligible.
Safety and efficacy assessments. The primary safety objective was to determine the MTD of bosutinib plus capecitabine in patients with solid tumours by examining the DLT rates within the dose cohorts. All patients who received at least one dose of study treatment were included in the safety evaluation, which included the incidence of AEs, physical examination, laboratory evaluations, 12-lead electrocardiogram, and left ventricular ejection fraction measurement. Safety events were graded for severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
Tumour assessments were performed for all patients at screening, and response was assessed every 6 weeks until disease progression or treatment discontinuation. No primary efficacy end point was specified; the secondary objective of antitumour activity was assessed based on best confirmed overall response according to RECIST version 1.0 (Therasse et al, 2000) and ORR (confirmed complete response (CR) or partial response (PR)).
RESULTS

Patients.
A total of 32 patients were enrolled in this phase 1 study between October 2009 and March 2011, among whom, the median age was 62 (range, 42-82) years (Table 3) . The majority of patients had a diagnosis of colorectal cancer (44%), breast cancer (34%), or pancreatic cancer (16%); cholangiocarcinoma and glioblastoma were each present in one patient. Most (69%) patients had previously received at least five antitumour treatment regimens for locally advanced or metastatic disease; 22% of patients had previously received capecitabine treatment.
The median study duration was 81.0 days (range, 22-420 days), with a median duration of treatment of 63.5 days (range, 19-419 days). All patients discontinued the study, the primary reasons for which included disease progression (n ¼ 26 (81%)), AEs (n ¼ 4 (13%)), death (n ¼ 1 (3%)), and patient withdrawal (n ¼ 1 (3%)).
Determination of the MTD. Because of the adaptive nature of the study design, all possible dose combinations shown in Table 2 were explored at least once, with the exception of bosutinib 400 mg per day plus capecitabine 625 mg m À 2 twice daily. The sequence of patient enrollment in each dose-escalation cohort is shown in Table 4 . Based on the observed toxicity, the MTD was determined to be bosutinib 300 mg per day plus capecitabine 1000 mg m À 2 twice daily on days 1-14 of each 21-day treatment cycle, with no DLTs observed for the two patients treated at the MTD during the doseescalation phase. An additional seven patients were subsequently Two patients were initially enrolled at the MTD level, for a total of 24 patients included in the initial DLT evaluation; an additional seven patients were subsequently enrolled at this dose level to allow further evaluation and confirmation of the MTD. One of the five patients treated at this dose level was excluded from the DLT evaluation because of no DLT and failure to receive X14 doses of bosutinib or X10 doses of capecitabine. enrolled at the MTD to confirm the selected dose, and again no DLTs were observed. Only one MTD was identified for this combination. Overall, 2 out of 31 (6%) evaluable patients experienced DLTs. The first patient was a 56-year-old woman with metastatic breast cancer who was receiving bosutinib 400 mg per day plus capecitabine 750 mg m À 2 twice daily and experienced grade 3 neurologic pain on study day 5. Bosutinib 400 mg per day was stopped on study day 8 and bosutinib 300 mg per day was started on study day 14, after the neurologic pain resolved to grade 1. The second patient was a 58-year-old woman with metastatic breast cancer who was receiving bosutinib 400 mg per day plus capecitabine 1000 mg m À 2 twice daily who experienced grade 3 increased alanine aminotransferase (ALT) and pruritus/rash, both of which resolved following temporary discontinuation of bosutinib. These DLTs were considered to be treatment related; association with either bosutinib or capecitabine treatment was not determined. One additional patient receiving bosutinib 200 mg per day plus capecitabine 1000 mg m À 2 twice daily experienced grade 2 fatigue, which later progressed to grade 4 severity one day after the 21-day DLT assessment period; because of this timing the event did not meet the DLT criteria. The recommended MTD of the combination would not have changed if this subject met the DLT criteria. Notably, DLTs resolved after temporarily stopping treatment and none of these events were considered by the investigators to be serious AEs.
Safety and tolerability. All 32 (100%) patients experienced at least one treatment-emergent AE among whom 29 (91%) experienced at least one treatment-related (bosutinib and/or capecitabine) AE. The most common treatment-related AEs, overall as well as within the MTD cohort, were diarrhoea, nausea, palmar-plantar erythrodysesthesia (PPE), fatigue, and vomiting (Table 5) . A total of 15 (47%) patients experienced at least one grade 3/4 treatment-related AE, most frequently PPE, increased ALT, and increased aspartate aminotransferase (AST; Table 5 ). Ten (31%) patients experienced at least one serious AE, including anaemia, atrial fibrillation, constipation, gastrointestinal obstruction, asthenia, chest pain, hemiparesis, renal impairment, acute respiratory distress syndrome, dyspnoea (n ¼ 1 each); bronchitis (n ¼ 2), and disease progression (glioblastoma multiforme (n ¼ 1), malignant neoplasm (n ¼ 2); pancreatic cancer (n ¼ 1)).
Although diarrhoea was common (n ¼ 23 (72%)), 91% (21 out of 23) of patients with diarrhoea experienced only maximum grade 1 or 2 events, all patients had their diarrhoea resolved (median (range) cumulative duration of 10 (1-267) days), and no patient discontinued treatment because of diarrhoea, suggesting that events were manageable. Two (9%) patients required dose interruption, and one (4%) patient had dose reduction in order to manage their diarrhoea events. Treatment-emergent AEs of grade 3/4 ALT or AST elevations were reported in three (9%) and three (9%) patients, respectively; these events were managed by dose interruption in two and two patients, respectively, and all resolved with no patient discontinuing treatment. Treatmentrelated haematologic AEs were relatively uncommon, with one patient each experiencing maximum grade 1 or 2 leukopenia, lymphopenia, neutropenia, and thrombocytopenia. Cardiac events were reported in five (16%) patients; four of these subjects with events considered drug related, one of which was a serious AE of atrial fibrillation observed in a patient with a history of peripheral arterial occlusive disease and hypertension, who was receiving Warfarin. Prolonged QT (grade 2) was reported in two patients, and decreased ejection fraction (grade 3) was reported in one patient; all had a prior history of cardiac disease. Most of the resolved cardiac events were transient, with cumulative median (range) duration of 16 (10-22) days, and all but one of the patients (grade 3 decreased ejection fraction) had their cardiac events resolve. Cumulative duration for this patient is unknown.
Grade 3/4 laboratory values were reported in nine (28%) patients on treatment, and included abnormal sodium values A DLT occurred in Cohort 2 at the time enrollment in Cohort 7 was initiated; however, during subsequent review, the corresponding AE (grade 3 ALT increased) was not deemed to be a DLT. After completion of Cohort 4, two additional patients were enrolled in Cohort 8 (same dose level) per protocol because Cohort 6 was already enrolling.
e Enrollment in subsequent cohorts after Cohort 8 was not required because enrollment of 24 evaluable patients had been completed as the last patient finished Cohort 8. f A DLT occurred in Cohort 8; however, during subsequent review, the corresponding AE (grade 4 fatigue) was deemed not a DLT during a subsequent review. This DLT did not affect cohort enrollment as 24 subjects had already been enrolled when C8 was finished.
(n ¼ 3); international normalised ratio, partial thromboplastin time, phosphorous, calcium, ALT, and prothrombin time (n ¼ 2 each); and glucose, AST, and haemoglobin (n ¼ 1 each). Grade 3/4 partial thromboplastin time and prothrombin time increases were reported in one patient both at baseline and on treatment. Based on electrocardiogram laboratory data, no patient had a QT or corrected QT (QTc) interval greater than 500 ms.
Bosutinib and capecitabine dose modifications due to AEs are shown in Table 5 . Bosutinib dose reduction and interruption due to an AE occurred in 9% and 34% of patients, respectively. Capecitabine dose reduction and interruption due to an AE occurred in 13% and 50% of patients, respectively. Four (13%) patients experienced AEs that led to treatment discontinuation; AEs included right hemiparesis (due to disease progression that led to death) and asthenia (n ¼ 1), fatigue (n ¼ 1), bronchitis (that led to death) and acute respiratory distress syndrome (n ¼ 1), and PPE syndrome (n ¼ 1). In addition, three other patients had AEs related to disease progression that led to treatment discontinuation, reported as malignant neoplasm (n ¼ 2) and glioblastoma multiforme (n ¼ 1). Of the AEs that led to treatment discontinuation, only PPE and fatigue were considered treatment related.
Overall, six (19%) deaths occurred during the study, with five deaths occurring within 28 days of the last study dose. Five of the six deaths were due to disease progression (primary diagnoses of pancreatic cancer (n ¼ 2); breast cancer, glioblastoma multiforme, and colorectal cancer (n ¼ 1 each)), whereas the other was due to an unrelated AE of bronchial infection (n ¼ 1). None of the deaths were considered drug related.
Antitumour activity. Among the intent-to-treat population (n ¼ 32), one patient with breast cancer and one patient with colorectal cancer achieved a confirmed PR; no patient achieved a (22) 3 (9) 3 ( AEs leading to treatment discontinuation include right hemiparesis (due to disease progression that led to death) and asthenia (n ¼ 1), fatigue (n ¼ 1), bronchitis (that led to death) and acute respiratory distress syndrome (n ¼ 1), and PPE (n ¼ 1). In addition, three other patients had AEs related to disease progression that led to treatment discontinuation, reported as malignant neoplasm (n ¼ 2) and glioblastoma multiforme (n ¼ 1).
CR (ORR: 6% (95% CI: 1-21%)). Stable disease (SD) lasting r24 weeks was observed in 10 patients (breast cancer (n ¼ 3); colorectal cancer (n ¼ 7)); SD lasting 424 weeks was observed in an additional 4 patients (breast cancer (n ¼ 2); colorectal cancer (n ¼ 2)). None of the patients with pancreatic cancer, cholangiocarcinoma, or glioblastoma achieved a response or SD. A total of 15 patients (cholangiocarcinoma (n ¼ 1); colorectal cancer (n ¼ 4); breast cancer (n ¼ 5); and pancreatic cancer (n ¼ 5)) had a best response of progressive disease. The response status of the patient with glioblastoma was indeterminate because the patient did not have any post-baseline tumour assessments and discontinued treatment before their week 6 assessment because of an AE.
DISCUSSION
The primary purpose of this study was to determine the MTD of bosutinib plus capecitabine in patients with select locally advanced or metastatic solid tumours. The MTD of this treatment combination was bosutinib 300 mg per day plus capecitabine 1000 mg m À 2 twice daily on days 1-14 of each 21-day cycle. A challenge in developing combination regimens incorporating a novel agent is whether the chemotherapy dose should be maximised with increasing doses of the novel agent, or whether the novel agent should be maximised with increasing doses of chemotherapy. The 'up-down' design allows for both possibilities to be explored, with the possibility of achieving up to three MTD levels for the combination. A similar 'up-down' design was used in a recent phase 1 study to evaluate the MTD of neratinib in combination with temsirolimus in patients with solid tumours (Gandhi et al, 2014) .
The 3 þ 3 design is the most common method for dose evaluation in phase 1 studies and has the advantages of ease of implementation and interpretation, together with the requirement for smaller numbers of patients (Le Tourneau et al, 2009; Liu et al, 2013) . However, drawbacks of this method include the need for a large number of dose escalation steps (e.g., X6 dose levels) and treatment of many patients at subtherapeutic doses, as well as uncertainty surrounding the recommended phase 2 dose identified (Le Tourneau et al, 2009) . In contrast, the 'up-down' design used in the present study allows for exploration of more dose combinations. Although the 'up-down' design allows for a more definitive identification of the MTD, the additional dose combinations evaluated require enrollment of additional patients. The simulation study also demonstrated that, compared with a specific 3 þ 3 design, more patients are evaluated closer to the MTD and fewer patients at toxic dose levels using the 'up-down' design. Moreover, the 'up-down' design mitigates the underestimation of the MTD that is associated with the 3 þ 3 design.
Notably, the MTD for bosutinib (300 mg per day) in combination with capecitabine in this study is lower than the therapeutic dose identified for bosutinib monotherapy in previous studies-500 mg per day in patients with chronic/advanced phase CML (Cortes et al, 2011 (Cortes et al, , 2012 and 400 mg per day in patients with advanced solid tumours (Daud et al, 2012) . In addition, the MTD identified for capecitabine (1000 mg m À 2 twice daily) in this study is lower than the 1250 mg m À 2 twice-daily dose recommended by the US Food and Drug Administration for metastatic breast cancer (XELODA Full Prescribing Information, 2013) . However, retrospective analysis of medical and pharmacy records from 141 patients with metastatic breast cancer treated with capecitabine 1250 mg m À 2 twice daily demonstrated greater toxicity at that dose than previously reported in clinical studies, supporting a starting dose of 1000 mg m À 2 twice daily (Hennessy et al, 2005) . Thus, the MTD dose of capecitabine identified in the current study (1000 mg m À 2 twice daily) may be better aligned with clinical practice than the 1250 mg m À 2 twice-daily dose, and it is within the range of doses (1000-1250 mg m À 2 twice daily) recommended by the National Comprehensive Cancer Network (National Comprehensive Cancer Network, 2014) .
In the present study, the combination of bosutinib and capecitabine (all dose combinations) was well tolerated, which might reflect the fact that 88% of patients received bosutinib at doses lower than 400 mg per day and 53% received capecitabine at a dose lower than 1000-1250 mg m À 2 twice daily. Comparing AE incidence between the MTD cohort (n ¼ 9) and all patients excluding those receiving the MTD (n ¼ 23), incidence was increased in MTD-treated patients for AEs commonly reported with bosutinib (i.e., diarrhoea, 89% vs 57%; increased ALT, 22% vs 9%; increased AST, 22% vs 4%), suggesting efficient selection of the MTD for bosutinib. In contrast, the most frequent AE reported with capecitabine across clinical trials-PPE (i.e., hand-foot syndrome)-was not elevated in patients receiving the MTD versus all other patients (33% vs 30%); it is unclear whether assessment of a higher dose of capecitabine (e.g., 1250 mg m À 2 twice daily) in the present study would have yielded different outcomes.
Consistent with the known AE profiles for bosutinib and capecitabine monotherapy, the AE profile of the combination of bosutinib and capecitabine was characterised mostly by mild gastrointestinal events (diarrhoea, nausea, vomiting), PPE, and fatigue. Grade 3/4 ALT and AST elevations were reported in o10% of patients, and were manageable with no patient discontinuing treatment because of these AEs. The toxicity profile previously observed for bosutinib monotherapy in phase 1 and 2 studies in solid tumours was also generally characterised by mild gastrointestinal events that occurred early during treatment, and manageable ALT and AST elevations (Campone et al, 2012; Daud et al, 2012) . Capecitabine has a well-established toxicity profile that is primarily characterised by high incidences of PPE, diarrhoea, nausea, vomiting, and stomatitis (Hennessy et al, 2005) . Comparing the incidences of treatment-related AEs in the present study with those previously published for capecitabine monotherapy at a dose of 2510 mg m À 2 daily in patients with paclitaxel-refractory metastatic breast cancer (Blum et al, 1999) , certain treatment-related AEs occurred at lower incidence in the present study (all patients), including PPE (31% vs 56%), nausea (41% vs 52%), and vomiting (25% vs 37%), whereas diarrhoea occurred at a higher rate in the present study (66% vs 54%). Notably, PPE events were not observed in studies evaluating bosutinib as monotherapy (Campone et al, 2012; Daud et al, 2012) ; thus, the occurrence of PPE events in the current study was likely attributable to capecitabine administration (XELODA Full Prescribing Information, 2013) .
The tolerability results in this study are comparable with those seen in a phase 1 study designed to identify DLTs and the recommended phase 2 doses of dasatinib (another dual Abl/Src TKI) plus capecitabine in women with advanced breast cancer (Somlo et al, 2013) . Consistent with the current study, some of the most common toxicities associated with dasatinib plus capecitabine observed in that study were gastrointestinal events (nausea, vomiting, and diarrhoea), PPE, headache, fatigue, and asthenia (Somlo et al, 2013) . Moreover, the overall rate of treatment-related grade 3/4 AEs reported here for bosutinib plus capecitabine (47%) is also consistent with those reported for dasatinib plus capecitabine (50%; Somlo et al, 2013) .
The observed efficacy results should be considered limited, given the lack of a prespecified efficacy end point and the small number of patients evaluated at the MTD (n ¼ 9). In this study, two patients (breast cancer, n ¼ 1; colorectal cancer, n ¼ 1) achieved a confirmed PR while receiving capecitabine at a lower dose than MTD (750 mg m À 2 twice daily) plus bosutinib 300 mg per day. A phase 1 study of bosutinib monotherapy administered over a range of escalating doses in patients with advanced solid tumours demonstrated a confirmed PR in one patient with breast cancer, an unconfirmed CR in one patient with pancreatic cancer, and SD in five patients with colorectal or lung cancer lasting 22-50 weeks (Daud et al, 2012) . In a phase 2 clinical study of single-agent bosutinib 400 mg per day in heavily pretreated patients with advanced breast cancer unselected for hormone receptor status, four patients achieved a confirmed PR; each of these four patients had hormone receptor-positive breast cancer (Campone et al, 2012) .
Studies of single-agent capecitabine 1250 mg m À 2 twice daily for the treatment of patients with advanced or metastatic breast cancer have reported ORRs ranging from 15 to 28% and SD rates (any duration) ranging from 30 to 46% (Blum et al, 1999 (Blum et al, , 2001 Reichardt et al, 2003; Fumoleau et al, 2004; Amari et al, 2010) . Patients with metastatic breast cancer treated with dasatinib plus capecitabine also achieved some clinical benefit in a phase 1 trial, as reflected by an ORR of 22% and an additional 30% experiencing SD lasting more than 24 weeks (Somlo et al, 2013) . The overall SD rate of 50% observed for dasatinib plus capecitabine is consistent with the overall SD rate with bosutinib plus capecitabine observed here (44%). In contrast, the ORR of 22% reported for the dasatinib plus capecitabine combination (Somlo et al, 2013 ) is higher than the ORR reported for capecitabine plus bosutinib reported here (6%; Somlo et al, 2013) . The observation that none of the patients with pancreatic cancer in this study achieved a CR or PR with bosutinib plus capecitabine treatment might be expected based on the results of a previous phase 2 study showing that only 3 of 41 patients receiving single-agent capecitabine for pancreatic cancer achieved a PR (ORR, 7%; Cartwright et al, 2002) . However, comparisons of response rates across these studies are complicated by variations in study design and in patients' baseline characteristics. For example, the current study was a phase 1 study with a limited number of breast cancer patients, most of whom had received substantial amounts of prior therapy, and who had received capecitabine doses lower than those associated with single-agent efficacy (1250 mg m À 2 twice daily; XELODA Full Prescribing Information, 2013).
The identification of patient subgroups most likely to benefit from therapy represents one of the major challenges in the development of novel targeted therapies in breast and other cancers; a number of clinical studies are currently ongoing to assess biomarkers predictive of response to dasatinib and other Src inhibitors in advanced solid tumours (Puls et al, 2011) . For example, a phase 1 study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab in patients with colorectal cancer showed that high expression levels of activated Src are predictive of improved response (Strickler et al, 2013) . However, these studies are generally limited by the difficulties in assessing correlations between biomarker levels with response, given the small numbers of treatment responders (Strickler et al, 2013) .
In conclusion, the combination of bosutinib plus capecitabine was associated with a manageable safety profile, which was primarily characterised by mild gastrointestinal events and similar to that previously observed for bosutinib or capecitabine monotherapy. Evidence supporting the efficacy of bosutinib plus capecitabine in patients with advanced solid tumours is limited; rigorous evaluation of the efficacy of bosutinib combined with capecitabine or with other agents for the treatment of advanced solid tumours, including breast cancer, awaits a suitably powered randomised clinical trial recruiting patients selected on the basis of Src inhibitor biomarkers that may optimise their treatment response.
